Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.13 USD
-0.09 (-4.05%)
Updated Apr 19, 2024 03:59 PM ET
After-Market: $2.14 +0.01 (0.47%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 39 | 60 | 31 | 34 |
Receivables | 0 | 0 | 0 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 5 | 5 | 5 |
Total Current Assets | 28 | 44 | 65 | 37 | 40 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 31 | 47 | 68 | 38 | 42 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 5 | 0 | 5 | 15 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 4 | 4 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 1 | 3 | 3 |
Total Current Liabilities | 9 | 12 | 5 | 12 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 5 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 13 | 14 | 12 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 534 | 516 | 510 | 453 | 431 |
Retained Earnings | -513 | -483 | -455 | -427 | -411 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 21 | 33 | 55 | 26 | 20 |
Total Liabilities & Shareholder's Equity | 31 | 47 | 68 | 38 | 42 |
Total Common Equity | 21 | 33 | 55 | 26 | 20 |
Shares Outstanding | 20.20 | 14.60 | 14.60 | 6.70 | 2.10 |
Book Value Per Share | 1.05 | 2.28 | 3.76 | 3.89 | 9.53 |
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 24 | 31 | 37 | 30 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 4 | 4 | 4 |
Total Current Assets | NA | 28 | 35 | 41 | 35 |
Net Property & Equipment | NA | 1 | 1 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 31 | 38 | 44 | 37 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 1 | 0 | 1 |
Current Portion Long-Term Debt | NA | 1 | 2 | 3 | 4 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 4 | 3 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 2 |
Total Current Liabilities | NA | 9 | 8 | 8 | 9 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 10 | 9 | 10 | 10 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 534 | 533 | 531 | 517 |
Retained Earnings | NA | -513 | -505 | -497 | -490 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 21 | 28 | 34 | 27 |
Total Liabilities & Shareholder's Equity | NA | 31 | 38 | 44 | 37 |
Total Common Equity | 0 | 21 | 28 | 34 | 27 |
Shares Outstanding | 65.40 | 20.20 | 19.40 | 19.40 | 19.40 |
Book Value Per Share | 0.00 | 1.05 | 1.46 | 1.75 | 1.37 |